To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Inclusion Criteria:

* The patient or his/her legal representative has signed a written informed consent form and dated it prior to any specific research procedure.
* Aged 18 years or older.
* Locally advanced or metastatic non-small cell lung cancer with NRG1 fusion detected by DNA or RNA-based next-generation sequencing (NGS) technology in tumor tissue specimens or liquid specimens.
* The patient has received platinum-based doublet chemotherapy previously.
* ECOG performance status score is 0\~2.
* The patient has sufficient bone marrow and organ functionality, which can be proved by complete blood cell count, blood biochemistry and urine biochemistry tests at baseline.
* The patient has measurable lesion(s).
* The female patient of childbearing age must adopt appropriate contraceptive measures and are not allowed to breastfeed a child.
* The male patient must voluntarily use contraceptives.

Exclusion Criteria:

* The patient has shown any severe or uncontrollable systemic disease sign that the investigators believe may significantly change the risk/benefit balance of the patient, including uncontrollable hypertension, high active bleeding tendency, active infection or significant damage of bone marrow or other functions.
* The patient has previously been treated with EGFR-TKI or any monoclonal antibody that acts on HER2/3.
* The patient has been found with symptomatic metastatic tumor of central nervous system (CNS).
* The patient has a history of interstitial pneumonia or radiation pneumonia requiring steroid therapy.
* The patient has not recovered yet from toxic reactions with CTCAE grade ≥3 (CTCAE5.0) caused by previous treatment.